Publications by authors named "P Chansriwong"
Article Synopsis
- DPYD polymorphisms are linked to toxicities from the chemotherapy drug 5-FU, and this study focused on identifying associations between specific DPYD gene variations and blood-related side effects in Thai colorectal cancer patients.
- Genetic testing revealed distinct frequencies of DPYD variants, with the homozygous variant DPYD*9A significantly correlating with neutropenia and other hematological toxicities during the first cycle of treatment.
- The findings suggest that the DPYD*5 variant may act as a predictive marker for lower toxicity levels, highlighting the importance of genetic profiling in managing 5-FU treatment risks.
Purpose: Androgen receptor splice variant 7 (ARV-7) is a resistance mechanism to hormonal therapy in metastatic castrate-resistant prostate cancer (mCRPC). It has been associated with poor outcomes. On progression to castrate resistance, ARV-7 positivity has been identified in global populations at an incidence of 17.
View Article and Find Full Text PDFBackground: EGFR inhibitor and immunotherapy have been approved for adjuvant treatment in resectable non-small cell lung cancer (NSCLC). Limited reports of molecular and clinical characteristics as prognostic factors in NSCLC have been published.
Methods: Medical records of patients with resectable NSCLC stage I-III diagnosed during 2015-2020 were reviewed.
Osimertinib has shown greater efficacy than standard epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and fewer grade 3 or higher adverse drug reactions (ADRs) in patients with advanced non-small cell lung cancer (NSCLC) harboring () mutations. However, the clinical outcomes of osimertinib treatment vary depending on the patient's ethnicity. Therefore, further research is necessary to evaluate the impact of single nucleotide polymorphisms (SNPs) in cytochrome P450 () and drug transporters on the therapeutic outcomes and ADRs to osimertinib in Thai patients, to provide improved pharmacological treatments for cancer patients.
View Article and Find Full Text PDFBackground: Information on genetic alterations, notably EGFR mutations, is important for guiding non-small-cell lung cancer (NSCLC) treatment. Circulating tumor DNA (ctDNA) analysis represents a less invasive alternative to tissue biopsy for analyzing mutation status, but its clinical value may vary across disease stages.
Objective: To explore clinical correlates of ctDNA and tissue/plasma-based EGFR mutation (EGFRm) status across all NSCLC stages.